2 suspended. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 2 |
Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome STX107 - Fragile X Syndrome | Phase 2 | Suspended | Seaside Therapeutics, Inc. | 16 | 2011-05-01 | 2012-12-20 |
Fragile X Syndrome (2) · Behavior (1) · Cognitive Dysfunction (1) · Neurobehavioral Manifestations (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Heredodegenerative Disorders, Nervous System (2) · Intellectual Disability (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Sex Chromosome Disorders (2) · X-Linked Intellectual Disability (2) · Cognition Disorders (1) · Mental Disorders (1) · Neurobehavioral Manifestations (1) · Neurocognitive Disorders (1)
Psilocybin (1)
Nova Mentis Life Science Corp (1) · Seaside Therapeutics, Inc. (1)
Canada (1) · United States (1)
David Crowley, MD (1) · Marvin Hausman, MD (1)